2023-505165-93-00招募中1 期
A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (9)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate CancerAdvanced Prostate Cancer2023-504063-17-00Janssen - Cilag International48
招募中
1 期
A Phase 1 Study of JNJ-87890387 for Advanced Solid TumorsAdvanced Solid Tumors2023-505358-16-00Janssen - Cilag International96
招募中
1 期
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma2024-513439-25-00Janssen Cilag International15
招募中
1 期
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLLNon-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)2023-504187-42-00Janssen - Cilag International52
招募中
1 期
A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHLRelapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies2024-514176-41-00Janssen Cilag International16